14 Peptides Legal Again in 2026? Status and Evidence Explained

“Fourteen peptides are legal again” is not an accurate description of a single regulatory action. This guide retains all fourteen subjects while separating current category entries, withdrawn nominations, advisory review, approved products and clinical research. The status of one form or route does not automatically apply to another.

The Fourteen Peptides Covered Here

This is a subject list, not a list of fourteen newly approved or uniformly reclassified medicines. Grouping by research interest does not establish a treatment indication:

Growth hormone secretagogues: Ipamorelin, GHRP-2, GHRP-6

GHRH analogue: CJC-1295

Tissue-repair research: BPC-157, TB-500 (not interchangeable with full-length thymosin beta-4)

Immune and neuroactive research: Thymosin alpha-1, Selank, Semax

Sexual-function research and an approved product: PT-141/bremelanotide

Skin, inflammation and metabolic research: GHK-Cu, AOD-9604, KPV, MOTS-c

Read the exact form, route and evidence in each section. Non-injectable GHK-Cu, GHRP-2/GHRP-6 and the finished bremelanotide product illustrate why one “legal again” label is misleading.

Growth Hormone-Related Peptides: GHS and GHRH Analogues

Ipamorelin stimulates growth hormone release. The often-cited selectivity finding comes from Raun and colleagues' 1998 experiments in rat cells, rats and swine, not a demonstration of minimal risk in people using it for sleep, body composition or recovery. The animal findings are a reason for research, not proof of those clinical benefits. FDA currently lists ipamorelin acetate among withdrawn nominations and separately under 503B Category 2.

GHRP-2 has human hormone-response evidence: a study in eight healthy men measured GH after intravenous GHRP-2, GHRH and their combination. That supports an acute physiological effect, not a long-term muscle, weight-loss or anti-aging outcome. The May 2026 503A document places GHRP-2 in Category 3; FDA's separate 503B risk entry specifies injectable and nasal routes.

GHRP-6 likewise has human GH-response research. A nine-man physiological study examined how blocking GHRH affected its GH response. It was not a trial validating a recovery stack or comparing long-term patient benefits. GHRP-6 is also in the May 2026 503A Category 3 document and the separate 503B Category 2 table.

CJC-1295 is a GHRH analogue. Teichman and colleagues studied a long-acting form in two short randomized trials in healthy adults, finding sustained GH/IGF-I increases and reporting no serious adverse reactions in those trials. Those results do not establish that it is among the safest peptides or validate a universal weekly treatment schedule. Do not transfer the long-acting study schedule to a product labeled “no DAC” or to a blend without establishing its identity. FDA's current table lists CJC-1295 among withdrawn nominations.

Regulatory sources: Compare the May 14, 2026 503A category document with FDA's framework-specific safety table. Category 3 and withdrawn nominations are not Category 1 authorization, and a 503A status must not be assumed to apply under 503B.

Tissue Repair and Recovery: BPC-157 and TB-500

BPC-157 has emerging human reports as well as preclinical research. For example, Lee and Padgett's knee-pain chart review contacted 16 of 17 patients; 12 had received BPC-157 alone and four had received BPC-157 with a preparation described as TB4. Many reported improvement. The study lacked a control group and standardized functional outcome measures, so it cannot establish tissue regeneration, comparative benefit or long-term safety. Reports of benefit deserve further testing, not dismissal or conversion into a proven recovery protocol.

TB-500 is not simply another name for full-length thymosin beta-4. FDA's 2026 TB-500 briefing evaluates a synthetic, N-acetylated seven-amino-acid fragment based on LKKTETQ, distinct from the 43-amino-acid parent peptide. It also notes inconsistent commercial naming. Evidence for the parent molecule or a differently identified “TB4” preparation must not automatically be attributed to that fragment.

The same briefing found no human clinical evidence for the evaluated TB-500 preparations and wound-healing use at the time of its review. This is an identified evidence gap, not proof that no one uses products sold under that name. Both BPC-157 and TB-500 appear in the FDA table of withdrawn nominations; the July advisory process did not itself create final compounding authorization.

Immune and Neuroactive Research: Thymosin Alpha-1, Selank, and Semax

Thymosin alpha-1 has been investigated in human immune-related conditions, but “immune support” is not one established clinical outcome. In the 2025 TESTS randomized trial, 1,106 adults with sepsis were enrolled and 1,089 entered the modified intention-to-treat analysis. It found no clear reduction in 28-day mortality compared with placebo; safety outcomes did not differ statistically significantly. The published correction updated survival analyses without establishing a mortality benefit. This specific result neither rules out every other potential use nor establishes general infection prevention or cancer-treatment benefit.

Selank has small human studies, including a Russian-language comparative trial in 62 patients with generalized anxiety disorder and neurasthenia: 30 received Selank and 32 medazepam. The English abstract reports similar anxiety effects and additional antiasthenic and psychostimulant effects with Selank. It does not provide enough numerical detail to establish a precise benefit estimate, long-term safety or equivalence to usual care. This is emerging clinical evidence, not proof of broad cognitive or immune enhancement.

Semax research includes rat neurotrophin gene-expression experiments and a 110-patient post-stroke rehabilitation study. The latter reported BDNF and functional-recovery improvements, but its abstract does not describe randomization or blinding. These findings warrant study; they do not establish memory or attention benefits in healthy students and athletes. Personal reports should be labeled as such rather than treated as controlled evidence.

For US compounding status, FDA's current table lists thymosin alpha-1, Selank acetate (TP-7) and Semax (heptapeptide) under withdrawn nominations. Foreign clinical use or a published study does not establish US approval or a newly authorized compounding pathway.

Sexual Function Support: PT-141 (Bremelanotide)

PT-141 is also known as bremelanotide. Its approved product is spelled Vyleesi, not Vylessi. The current prescribing information identifies a specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women, with distress or interpersonal difficulty, when the low desire is not attributable to another medical or psychiatric condition, relationship problems or a medication or drug.

Vyleesi is a melanocortin receptor agonist. It is not indicated for men, postmenopausal women or sexual-performance enhancement. Its label contraindicates use with uncontrolled hypertension or known cardiovascular disease. This is not a complete prescribing summary.

Vyleesi's initial US approval was in 2019, not a new fourteen-peptide reclassification in 2026. Approval of this finished injection does not extend to every compounded bremelanotide preparation. Off-label prescribing of an approved medicine and lawful compounding are separate questions; this page does not establish a newly authorized or necessarily cheaper compounded alternative.

Skin, Inflammation and Metabolic Research: GHK-Cu, AOD-9604, KPV, and MOTS-c

GHK-Cu is a copper-peptide complex with connective-tissue research. Maquart and colleagues reported increased collagen and other matrix components in rat wound chambers. That experiment does not establish a human injectable skin-rejuvenation protocol. Regulatory status also depends on route: non-injectable GHK-Cu appears in the May 2026 503A Category 1 document, while injectable GHK-Cu is listed among withdrawn nominations. Neither entry is approval of every GHK-Cu product.

AOD-9604 is a modified growth-hormone fragment studied for lipid metabolism. Its obesity-development program included human trials, but the sponsor's February 2007 announcement reported no statistically significant weight-loss benefit over placebo at 12 or 24 weeks in the larger oral study and ended that program. That result does not rule out every future formulation, but it does not support a proven injection-based fat-loss claim either. Fat breakdown and fat-cell death are different processes; this page does not substantiate the former claim of weight loss through fat-cell apoptosis.

KPV is the tripeptide Lys-Pro-Val. Dalmasso and colleagues reported PepT1-mediated uptake and reduced inflammatory signaling in human-derived cells, alongside reduced inflammation in mouse colitis models. The paper attributes the studied effect to PepT1-mediated uptake rather than melanocortin-receptor activation. These are preclinical findings, not established treatment effects in people with Crohn's disease or ulcerative colitis.

MOTS-c is a mitochondrial-derived peptide. Lee and colleagues' foundational research reported protection against diet-induced obesity and insulin resistance in mice. That supports a metabolic research rationale; it does not demonstrate that administering MOTS-c improves those outcomes in people. Human measurements of an endogenous peptide and trials administering a preparation answer different questions.

FDA's withdrawn-nomination table includes AOD-9604, KPV and MOTS-c. Research activity and an advisory review do not themselves establish an approved product or a final compounding pathway.

Why the “Five Remaining Banned” Summary Is Unreliable

The May 14, 2026 503A document does not show this page's fourteen subjects moving together to Category 1 with five unnamed peptides left behind. It separately lists non-injectable GHK-Cu in Category 1 and GHRP-2/GHRP-6 in Category 3. The current risk table also has 503B-specific entries and withdrawn nominations.

A substance may therefore be discussed in more than one context. Do not turn these lists into a ranking of the “best fourteen” or assume that a withdrawal means safety concerns have been resolved. Future decisions must be checked individually rather than predicted from an unnamed remainder.

Understanding Category 1 vs Category 2 Under 503A and 503B Rules

Under FDA's 503A interim policy, Category 1 describes potentially eligible nominations with enough supporting information for evaluation, subject to policy conditions. It is not finished-drug approval or a guarantee of safe preparation. Category 2 identifies significant safety concerns; Category 3 concerns insufficient nomination information. Neither receives the Category 1 policy.

Statutory ingredient pathways are a separate check, including applicable monographs, approved-drug components where no monograph exists, and the final bulks list where neither applies. A withdrawn nomination does not automatically satisfy one of those pathways. Prescriptions, quality and other requirements still matter.

The 503B framework has different bulk-ingredient requirements and a separate interim policy. Do not transfer a 503A status to an outsourcing facility. See the category and compounding explainer for the prescription, quality and state-authorization distinctions.

What the 2023 Restrictions Actually Described

FDA's dated risk entries describe substance-specific concerns and differing levels of information, not a finding that every peptide is equally risky or every vial contaminated. Issues include ingredient characterization, impurities, possible immune responses and reported adverse events. The meaning depends on the substance, route and framework.

Patients and clinicians may report benefits despite those uncertainties. Such observations can motivate research without establishing causality, universal safety or compliance of a particular supply chain. Regulatory assessment and scientific assessment should inform each other without being treated as identical.

Timeline of Peptide Regulation Changes

2023: FDA's risk table records September additions alongside other dates and framework-specific entries. The historical label “ban” needs that context.

May 2026: the 503A update records non-injectable GHK-Cu's return to Category 1 after clarification that a withdrawal was intended for injectable use. This is a specific route distinction, not a uniform fourteen-peptide change.

July 2026: PCAC considered BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon for the 503A bulks list. The advisory process is separate from a final FDA action.

For any later change: check the actual FDA document, publication date, substance identity and conditions. An announcement or projected timetable is not a substitute for the operative status. This article does not promise when any preparation will become available.